Genmab-Merus deal US antitrust deadline set to expire Nov. 12
Genmab and cancer drugmaker Merus have filed paperwork with the US antitrust authorities for their $8 billion deal and the waiting period under the Hart-Scott-Rodino Act is set to expire on...To view the full article, register now.
Already a subscriber? Click here to view full article